
    
      This is a special drug use surveillance on long-term use of alogliptin with a 1-year
      (12-month) observational period, designed to investigate the safety and efficacy of long-term
      combination therapy with alogliptin and biguanides in participants with type 2 diabetes
      mellitus in the routine clinical setting.

      Participants diagnosed with type 2 diabetes mellitus who responded inadequately to treatment
      with biguanides in addition to diet therapy and exercise therapy will be enrolled. The
      planned sample size is 1,000.

      The usual adult dosage for oral use is 1 alogliptin tablet (25 mg) once daily.
    
  